Kornimate/medical-research-clean huggingface dataset:
combination therapy of low doses of rfviia and feiba for severe hemophilia a patients with an inhibitor to factor viii

Conditions: Hemophilia A

Summary: patients with severe hemophilia and inhibitors can be treated effectively by activated prothrombin complex concentrates (apcc, eg. feiba) or high dose recombinant factor viia (rfviia). rarely, such patients develop refractoriness to these products for whom therapy with sequential feiba and rfviia has been recently suggested. the impetus for the present report was a hemophilia a patient with high titer inhibitor (1300bu) who had life threatening hematuria that was resistant to repeated doses of 400µg/kg rfviia up to a cumulative dose of 1200 µg/kg given over 6-9 hours. thrombin generation (tg) tested in vitro was consistent with resistance to high concentrations of rfviia but yielded good response to combinations of low doses of rfviia+feiba. in a desperate attempt to control the bleeding, concomitant therapy of 25 u/kg feiba and 40µg/kg rfviia was infused and resulted in arrest of bleeding within minutes. over a span of about one year the patient has been successfully treated by this combination for more than 200 bleeding episodes in muscles and joints.

inhibitor patients with hr inhibitors were eligible for study enrollment. after consent blood was drawn and ex- vivo spiked with rfviia/feiba and combinations, assayed by thrombin generation tests. the combination yielding sufficient hemostasis was depicted for patients' therapy of future bleeding episodes. following actual therapy hemostasis and safety parameters were monitored.

Eligibility criteria:
inclusion criteria: * hemophilia patients with inhibitors * patients signing informed consent exclusion criteria: * patients under 16 or above 65 * patients with allergic reaction or adverse events in previous use the concentrates * patients with high risk of thrombosis
the effect of act and float rest on burnout syndrome.

Conditions: Burnout Syndrome

Summary: in 1982, steven hayes, a clinical psychologist, developed acceptance and commitment therapy (act), a unique empirically based psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility. in 1954, john lilly, a cognitive neuroscientist, developed the sensory deprivation tank (known today as floatation restricted environmental stimulation therapy - float rest), to access a wide range of healing, higher brain functions, and meditation through an unparalleled deep relaxation state. in this study, the investigators aim to examine whether participants in the act + float rest condition will have larger decreases of the burnout phenomenon than those who receive either only act or float rest.


Eligibility criteria:
low dose dexmedetomidine as a postoperative pain adjunct

Conditions: Spinal Fusion; Adolescent Idiopathic Scoliosis

Summary: this randomized controlled trial examines whether the addition of a low-dose dexmedetomidine infusion to our current multimodal pain management plan decreases narcotic consumption and reduces side effects in adolescent patients undergoing posterior spinal fusion for idiopathic scoliosis.

patients will assigned to one of two groups. either the intervention group where they will receive a dexmedetomidine infusion at 0.2mcg/kg/hr for 48 hours post-operatively or the control group where they will receive a normal saline infusion for 48 hours post-operatively in addition to our hospitals standard pain management protocol. pain scores will be recorded and patients will fill out a brief questionnaire every 48hours about their pain control and side effects (pruritus, nausea, vomiting, drowsiness).

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic scoliosis * undergoing a posterior spinal fusion of at least 5 levels with both thoracic and lumbar involvement exclusion criteria: * known allergy to dexmedetomidine or any of the standard medications used intra or post operatively * patients with a history of chronic pain currently taking opioids, tca's, gabapentinoids * medical contraindications to administration of dexmedetomidine, unstable cardiac status, (prolonged qtc, life threatening arrhythmias, use of digoxin) * moya moya disease

Keywords: pain management narcotic sparing pediatric dexmedetomidine
inhalation of lidocaine before intubation

Conditions: Sore Throat

Summary: we investigate the potential benefits of ultrasound-driven lidocaine inhalation immediately before induction.

sudden increases in blood pressure and heart rate after tracheal intubation and post-operative sore throat are two common undesirable side effects of general anesthesia and might lead to patients' morbidity or dissatisfaction. we investigated the possibility to attenuate both side effects with one single method, i.e. ultrasound-driven lidocaine inhalation immediately before induction.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i or ii. patients scheduled for elective surgery under general anesthesia with orotracheal intubation exclusion criteria: * patient's refusal to join, major surgery or expected operation duration longer than 3 hours, patients with a anticipated difficult airway, requiring a nasogastric tube in peri-operative stage, having recent upper respiratory tract infection (within 1 week) or pre-existing sore throat.

Keywords: anesthetics, local, lidocaine; nebulizers and vaporizers; complications, intubation, intratracheal.
blood cell adhesion to arterial filters during cardiac surgery

Conditions: Blood Coagulation Disorders; C.Surgical Procedure; Cardiac

Summary: cardiopulmonary bypass (cpb) is a unique clinical scenario that results in widespread activation of the hemostatic system. conventional cpb interferes with normal hemostasis by diluting hemostatic cells and proteins, through reinfusion of shed blood, and through activation on the bypass circuit surface of multiple systems including platelets, the kallikrein-kinin system, and fibrinolysis . besides, deleterious effects of cardiopulmonary bypass (cpb) are partly sequelae of blood-foreign surface reactions. the arterial filter is the part of the cpb circuit where blood cells are exposed to high mechanical stress and where cellular aggregates may fasten in large quantitiesiec.

this is a clinical and observational study. it is being performed in the surgical center and intensive care unit of the heart institute (incor) from faculty of medicine, university of são paulo (fmusp), on patients undergoing cardiac surgery, who satisfy inclusion and exclusion criteria. in the preanesthetic visit, patient assessment of the criteria described in study methodology is verfied. during the surgery, a blood sample is taken to analyze hemostatic function in the begin of cardiopulmonary bypass, before arterial filter (pre-filter) and in the end of cardiopulmonary bypass, after arterial filter (post-filter). other routine laboratory exams is being colected until first postoperative day, on the eletronic medical records. at the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by sem. ten arterial filter samples from pre-determined sites and sizes are sent to the clinical laboratory for evaluation of platelet and leukocyte gene expression in arterial filter. patients will be followed until hospital discharge or 28 days after surgery, regarding allogeneic transfusion needs, reoperation and thromboembolic events.

Eligibility criteria:
inclusion criteria: * cardiac surgeries with extracorporeal circulation in patients older than 18 years * written and signed informed consent * preanesthetic assessment and preoperatory exams in accordance with study methodology exclusion criteria: * active infection; * previously coagulopathy; * antiplatelet therapy use until 10 days before surgery (except acetylsalicylic acid and enoxaparin that may be used in prophylactic doses until 24h before surgery);
a follow-up study to evaluate the safety of allo-asc-dfu in allo-asc-dfu-302 clinical trial

Conditions: Diabetic Foot Ulcer

Summary: this is a follow-up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 3 clinical trial (allo-asc-dfu-302) for 24 months

this is an open-label follow up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 3 clinical trial (allo-asc-dfu-302) for 24 months. allo-asc-dfu is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (vegf) and hepatocyte growth factor (hgf), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a diabetic foot ulcer.

Eligibility criteria:
inclusion criteria: 1. subjects who are treated with allo-asc-dfu sheet or vehicle sheet in phase 3 clinical trial of allo-asc-dfu-302. 2. subjects who are able to give written informed consent prior to study start and to comply with the study requirements. exclusion criteria: 1. subjects who are considered not suitable for the study by the principal investigator.
nrp104, adderall xr or placebo in children aged 6-12 years with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to assess, in a controlled environment, the efficacy and safety of nrp104 and adderall xr compared to placebo in treatment of children, aged 6-12, with adhd.


Eligibility criteria:
inclusion criteria: * males and non-pregnant females, aged 6-12 years dsm-iv-tr criteria for diagnosis of adhd, combined or hyperactive-impulsive subtypes * on stable regimen of stimulants for at least one month in the last six months and has shown adequate response to stimulants without unacceptable side effects exclusion criteria: * co-morbid psychiatric diagnosis such as psychosis, bipolar illness, severe ocd, severe depressive or anxiety disorder * history of seizure during the last 2 years, a tic disorder or tourette's * clinically significant ecg or laboratory abnormalities at screening or baseline * taking clonidine or anticonvulsant drugs * taking medications that affect blood pressure or heart rate
a study of mirikizumab (ly3074828) in children and teenagers with ulcerative colitis (uc)

Conditions: Ulcerative Colitis

Summary: this study was designed to evaluate how the body processes and removes mirikizumab. the study also evaluated safety and disease response in pediatric participants with uc taking mirikizumab. the study lasted about 52 weeks and included up to 18 visits.


Eligibility criteria:
inclusion criteria: * participants weighing \>10 kg * participants must have a diagnosis of ulcerative colitis for at least 3 months before the planned start date for the study medications * participants must have moderately to severely active uc as defined by a modified mayo score (mms) within 14 days before the first dose of study treatment * participants must have evidence of uc extending proximal to the rectum * participants must have demonstrated an inadequate response to, a loss of response to, or an intolerance to corticosteroids, immunomodulators, janus kinase inhibitor (jak-inhibitor) or to biologic therapies for uc exclusion criteria: * participants must not have a current diagnosis of crohn's disease, inflammatory bowel disease-unclassified (indeterminate colitis), ulcerative proctitis, or primary sclerosing cholangitis * participants must not have had surgery to remove part of their colon * participants must not have current evidence of toxic megacolon * participants must not have received any of the following for treatment of uc: cyclosporine or thalidomide within 30 days of screening; corticosteroid enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 1 week of screening endoscopy * participants must not have had an inadequate response to interleukin-12 p40 subunit antibody (anti-il12p40) (e.g. ustekinumab) or had prior exposure to anti-il-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab)

Keywords: interleukin-23 (il-23) antibody il-23p19 pediatric
digital versus conventional impression technique in mandibular arch

Conditions: Edentulous Jaw

Summary: objectives: passive fit of screw retained frameworks is essential to avoid biological and mechanical failures in addition to transmission of unfavourable stresses to the bone-implant interface. however, several factors contribute to the passive fit of screw retained prosthesis such as relative parallelism between the implants, implant number, impression material, impression technique and method of prothesis fabrication. the current study aims to evaluate the accuracy of three different impression techniques on the fit of screw retained bar splinting two inter-foraminal implants. methods: the study presents evaluation of the passive fit of screw retained bar fabricated with three different impression techniques.

surgical guide will be designed for completely edentulous patients. it will be inserted into the patient's mouth, stabilized against the upper denture and secured in place. dental implants will then be placed. for bar fabrication using the first impression technique, closed-top primary impressions will be made followed by open top secondary impression. extraoral scanning of the impression will be done followed by digital fabrication of the bar. for bar fabrication using the second impression technique, scanning of the lower arch will be done using omnicam intraoral scanner. scanning will be done by a single calibrated operator who is trained on intraoral scanning techniques. scan bodies will be then screwed to the implants and scanning will be done. both scans will be previewed on the computer desktop and superimposed together. a standard tessellation language file will be then exported, downloaded and previewed in inlab exocad software .implant system and the bar design will be selected from the software library. then, the standard tessellation language file will be exported to the milling machine and milling of cobalt chromium bar will be done. for bar fabrication using the third technique, splinting of scan bodies will be done followed by intraoral scanning of the lower arch.

Eligibility criteria:
inclusion criteria: * - patients' age range from 50 to 65 years old. * good oral hygiene is mandatory. * sufficient restorative space (15mm) to accept implant supported over denture diagnosed by mounting the diagnostic casts. * firm and healthy mucosa covering the alveolar ridge. * minimum bone width 5.5 mm buccolingually and of 12 mm bone height as diagnosed from the pre-operative cone beam computed tomography scan. exclusion criteria: * heavy smokers. * patients with para functional habits. * tempromandibular joint disorders. (tmj disorders) * patients with systemic disorders that may affect the results of this study. * v-shaped dental arch.
dexmedetomidine for immediate perioperative analgesia in pediatric patients undergoing tonsillectomy

Conditions: Tonsillitis

Summary: the primary purpose of this study is: 1. to compare dexmedetomidine with fentanyl in terms of intra-operative hemodynamics and post-operative analgesia. 2. to determine an analgesic dose response relationship for dexmedetomidine. 3. compare recovery characteristics of dexmedetomidine to fentanyl.


Eligibility criteria:
inclusion criteria: * all of the following criteria must be met for the potential subject to be eligible for participation: 1. the subject is 2 to 12 years of age 2. the subject's american society of anesthesiologists physical status is asa i or ii (see appendix 1). 3. the subject is scheduled for elective tonsillectomy with or without adenoidectomy surgery (procedures with myringotomy tube placement are allowed). 4. the subject will be hospitalized overnight after surgery 5. the subject's parent/legally authorized guardian has given written informed consent to participate; and where applicable, the subject has given appropriate assent to participate. exclusion criteria: * the potential subject is not eligible for participation if any of the following exclusion criteria apply: 1. the subject has a history or a family (parent or sibling) history of malignant hyperthermia 2. the subject has known significant renal or hepatic disorders determined by medical history, physical examination or laboratory tests. 3. the subject has a known or suspected allergy to opioid analgesics 4. the subject is a pregnant or lactating female (if post-menarcheal, a negative pregnancy test must be confirmed prior to the planned surgery time (in amsac) consistent with current standard of care. 5. the subject has history of. cardiovascular issues which would preclude the use of dexmedetomidine, (e.g. down's syndrome, dysrhthymias, conditions where hypotension is to be avoided).

Keywords: dexmedetomidine, fentanyl, tonsillectomy and adenoidectomy,
preparation rich in growth factors (prgf) treatment for osteoarthritis of the knee

Conditions: Osteoarthritis of the Knee

Summary: to evaluate the influence of prgf treatment on patient suffering from oa knee

autologous platelet-secreted growth factors (gfs) may have therapeutic effects in osteoarthritis (oa) capsular joints via multiple mechanisms. our aim is to examine the effect of a platelet-derived preparation rich in growth factors (prgfs) in oa knee

Eligibility criteria:
inclusion criteria: * age 40-75 years old * diagnosed oa of the knee more then 1 year * no knee deformation exclusion criteria: * mental of physical disabilities * pregnancy * deformities of the knee
oursleepkit to support cpap adherence

Conditions: Obstructive Sleep Apnea; CPAP Treatment; Treatment Adherence

Summary: the goal of this clinical trial is to learn if a couple-focused mobile health intervention will improve the use of continuous positive airway pressure (cpap), the primary treatment option for obstructive sleep apnea (osa). participants include newly diagnosed patients with osa who are candidates for cpap treatment and their partners. the couples will received supportive information and resources on their mobile devices before cpap begins and continuing for 6 months into cpap treatment. their interaction with the resources is self-paced and the time sent engaging with the information is up to them. participants will be asked to answer questions independently at five points: before cpap, and after using cpap for 1-week, 1-month, 3-months and 6-months. those questions are about their experience of using cpap, how the partner is involved in cpap treatment, and symptoms and quality of life. at the end of the study, some couples may be contacted for a virtual discussion about your experience regarding study participation which lasts approximately 1 hour.


Eligibility criteria:
inclusion criteria: * patients should be males or females (age≥18 years) with diagnosed osa and candidates for cpap therapy (with any type of pressure delivery mode), and are cohabiting with their partner for at least one year * the partners of eligible patients will be recruited if they are not diagnosed with osa and not using cpap * both partners should have their own mobile devices with access to the internet exclusion criteria: * have a diagnosis of a sleep disorder other than osa based on a polysomnogram (e.g., central sleep apnea, narcolepsy, or periodic limb movement disorder) * have planned bariatric surgery (as they typically quit cpap after surgery) * have a partner using cpap * are pregnant because the changes in respiration and sleep quality occurring with pregnancy may confound the results. * couples with one or both partners doing regular overnight shift work or those unable to speak or write in english will be excluded.

Keywords: obstructive sleep apnea cpap treatment mobile health treatment adherence dyadic coping couple
comparison of two biphasic insulin aspart 30 formulations (current and new formulation) in healthy volunteers

Conditions: Diabetes; Healthy

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers.


Eligibility criteria:
inclusion criteria: * bmi (body mass index) between 18 and 28 kg/m\^2, both inclusive * subject is a nonsmoker for at least 3 months * subject is judged to be in good health on the basis of their medical history, physical examination, ecg (electrocardiogram), and routine laboratory data * fasting plasma glucose between 80 and 110 mg/dl exclusion criteria: * •any clinically significant disease history of systemic or organ disease * •clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening (any abnormality should be discussed with the clinical monitor) * •in females of child bearing potential: pregnancy, lactating, breastfeeding, intent to become pregnant within the next 6-months or judged to be using inadequate contraceptive measures (adequate contraceptive measures include: condom, intrauterine devices). ß-hcg pregnancy test must be negative
mental health and its correlates among chinese adolescents exposed to the novel coronavirus disease 2019

Conditions: Mental Disorder

Summary: background: direct exposure to public health emergencies is associated with increased mental disorders. it is less clear about the prevalence of common mental disorders and its correlates in chinese adolescents after experiencing public health emergencies. objective: this longitudinal study aims to estimate the prevalence of common mental disorders (i.e. depression, anxiety, and post-traumatic stress disorder) and its correlates in a sample of chinese adolescents after experience a public health emergency, namely the novel coronavirus disease 2019 (covid-19). method: this study intends to recruit 3,428 chinese adolescent students from high and middle schools in the baseline survey. this study will track these recruited participants every 6 months via three-wave follow-up (i.e. 6-month, 12-month, and 18-month follow-ups). the demographics (e.g. age, gender, education, family background, and residence) and psychosocial factors (i.e. exposure to traumatic events, religious belief, social media exposure, loneliness, and perceived social support) associated with common mental disorders (i.e. depression, anxiety, and post-traumatic stress disorder) will be investigated in this sample population. furthermore, a hardcopy self-report questionnaire will be disturbed to all participants. additionally, the cross-sectional analyses will be first conducted to estimate the prevalence of mental disorders and their correlates in data of baseline survey. after obtaining the longitudinal data, the relative risk, incident rate ratios, latent class analysis, and structural equation model may be performed in this study. missing data will be solved by the multiple imputations. data analysis tools included the stata 16.0 and mplus 8.4. discussion: this longitudinal study will better help to understand the prevalence changes of mental disorders among chinese adolescents following the covid-19. these findings have the potential to provide empirical evidence about the burden of mental disease and key drivers of chinese adolescents following the covid-19, which can benefit the formation of public policy and mental health intervention programming. this study will close the gaps that a lack of epidemiological studies about the mental disorder prevalence and related risk factors.


Eligibility criteria:
inclusion criteria: 1. age range: 10-19; 2. full-time students in these targets high or middle schools; 3. nationality: china; 4. exposure context: covid-19; 5. able to adequately understand the content of consent form and questionnaire; (d) able to sufficiently state the purpose of the research and acknowledge the potential risks and benefits based on the questionnaire